Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study

Red blood cell (RBC) transfusions for anemia associated with lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) often contribute to reduced quality of life (QOL). Thus, reduction in RBC transfusion dependency (TD) is a primary therapeutic goal. Imetelstat is a firstin-class, competitive telome...

Descripció completa

Dades bibliogràfiques

Autors principals:	Mikkael A. Sekeres, Amer M. Zeidan, Valeria Santini, Rami S. Komrokji, Pierre Fenaux, Michael R. Savona, Yazan F. Madanat, David Valcárcel, Antoine Regnault, Kristin Creel, Libo Sun, Ying Wan, Shyamala Navada, Tymara Berry, Faye Feller, Uwe Platzbecker, María Díez-Campelo, Esther Natalie Oliva
Format:	Artigo
Idioma:	Inglês
Publicat:	Ferrata Storti Foundation 2026-01-01
Col·lecció:	Haematologica
Accés en línia:	https://haematologica.org/article/view/13107
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!